Argininemia, also called arginase deficiency, is an autosomal recessive urea cycle disorder where adeficiency of the enzyme arginase causes a buildup of arginine and ammonia in the blood.

The global Argininemia Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Argininemia Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Argininemia Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Helsinn Healthcare
Novartis Pharmaceuticals
Horizo​​n Pharma
Medicis Pharmaceutical
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Oral
Injection

Segment by Application
Hospital
Drugs Stores
Other